Literature DB >> 10958945

H-RAS, K-RAS, and N-RAS gene activation in human bladder cancers.

B Przybojewska1, A Jagiello, P Jalmuzna.   

Abstract

Bladder cancer is one of the leading causes of cancer death in most developed countries. In this work, 19 bladder cancer specimens, along with their infiltrations of the urinary bladder wall from the same patients, were examined for the presence of H-RAS, K-RAS, and N-RAS activation using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. The H-RAS activation was found in 15 (about 84%) of the 19 bladder cancers studied. The same results were obtained in the infiltrating urinary bladder wall samples. N-RAS gene mutations were observed in all cases (except 1) in which H-RAS gene mutations were detected. The results suggest a strong relationship between H-RAS and N-RAS gene activation in bladder cancer. Changes in the K-RAS gene in bladder cancers seem to be a rare event; this is in agreement with findings of other authors. We found activation of the gene in one specimen of bladder cancer and its infiltration of the urinary bladder wall in the same patient.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10958945     DOI: 10.1016/s0165-4608(00)00223-5

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  18 in total

1.  Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells.

Authors:  A Rose; M Grandoch; F vom Dorp; H Rübben; A Rosenkranz; J W Fischer; A-A Weber
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis.

Authors:  Lan Mo; Xiaoyong Zheng; Hong-Ying Huang; Ellen Shapiro; Herbert Lepor; Carlos Cordon-Cardo; Tung-Tien Sun; Xue-Ru Wu
Journal:  J Clin Invest       Date:  2007-01-25       Impact factor: 14.808

3.  Association between clinical characteristics and expression abundance of RTKN gene in human bladder carcinoma tissues from Chinese patients.

Authors:  Jie Fan; Li-Jie Ma; Shu-Jie Xia; Long Yu; Qiang Fu; Chao-Qun Wu; Xing-Hua Huang; Jian-Ming Jiang; Xiao-Da Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-12-14       Impact factor: 4.553

4.  Time-dependent biological differences in molecular markers of high-grade urothelial cancer over 7 decades (ras proteins, pTEN, uPAR, PAI-1 and MMP-9).

Authors:  Jorunn Litlekalsoy; Jens G Hostmark; Daniela Elena Costea; Martin Illemann; Ole Didrik Laerum
Journal:  Virchows Arch       Date:  2012-10-06       Impact factor: 4.064

5.  Promoter hypomethylation as potential confounder of Ras gene overexpression and their clinical significance in subsets of urothelial carcinoma of bladder.

Authors:  Kiran Tripathi; Apul Goel; Atin Singhai; Minal Garg
Journal:  Mol Biol Rep       Date:  2021-02-23       Impact factor: 2.316

6.  K-RAS mutation in transitional cell carcinoma of urinary bladder.

Authors:  S Ayan; G Gokce; H Kilicarslan; O Ozdemir; E Yildiz; E Y Gultekin
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

7.  Detection of mutated K-ras DNA in urine, plasma, and serum of patients with colorectal carcinoma or adenomatous polyps.

Authors:  Ying-Hsiu Su; Mengjun Wang; Dean E Brenner; Pamela A Norton; Timothy M Block
Journal:  Ann N Y Acad Sci       Date:  2008-08       Impact factor: 5.691

8.  Genetic aberrations of the K-ras proto-oncogene in bladder cancer in relation to pesticide exposure.

Authors:  Diaa A Hameed; Heba A Yassa; Michael N Agban; Randa T Hanna; Ahmed M Elderwy; Mohamed A Zwaita
Journal:  Environ Sci Pollut Res Int       Date:  2018-04-12       Impact factor: 4.223

9.  A melanoma molecular disease model.

Authors:  Smruti J Vidwans; Keith T Flaherty; David E Fisher; Jay M Tenenbaum; Michael D Travers; Jeff Shrager
Journal:  PLoS One       Date:  2011-03-30       Impact factor: 3.240

10.  A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.

Authors:  Gottfrid Sjödahl; Martin Lauss; Sigurdur Gudjonsson; Fredrik Liedberg; Christer Halldén; Gunilla Chebil; Wiking Månsson; Mattias Höglund; David Lindgren
Journal:  PLoS One       Date:  2011-04-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.